NEW ENGLAND HEALTHCARE EXECUTIVE NETWORK MEETING
CHINA’S FUNDING OPTIONS AND MARKET ACCESS
ACCELERATE TIME TO MARKET IN CHINA’S HEALTH SYSTEM
NOVEMBER 5, 2018, 7:30AM TO 10:00AM
FOLEY HOAG LLP
155 Seaport Boulevard
For Driving and Parking Information, Click Here
Despite the turmoil brewing over an unfolding trade war, China remains a critical opportunity for pharmaceutical and medical device/IVD technology companies. With a growing middle class and the government dedicated to improving the quality of health care, and billions of dollars in life science innovation, companies willing to invest the time and resources can achieve sales growth in the coming years in the 2nd largest and fastest growing life science market in the world.
China has 5 times the U.S. population with extremely concentrated care. For instance, in the case of annual outpatient visits, China 1st Affiliated Hospital of Zhengzhou University has 100 million annual outpatient visits, nearly 70x that of Massachusetts General Hospital’s 1.5 million annual outpatient visits. Government policies, aging population, unique demographics, hunger for western life science technology, new EU MDR challenges …. many factors making China an attractive first stop for market entry.
Grace Fu Palma, CEO, China Med Device
Grace has successfully helped many U.S. Medtech/IVD/combination products’ companies in their entry and expansion into the China Healthcare Market. With 20+ years of experience driving commercialization, partnerships, and CFDA regulatory and CRO services for both large multinationals and startup companies.
Alan has global senior management experience enhancing investor value, including execution of successful cross boarder M&A transactions, fundraising, IPO’s and private placements.
Shalabh Chandra, VP and GM of Neurology, Quest Diagnostics
Shalabh was the prior CEO and President of Analogic Asia and lived in Shanghai for 6 years.
Jian Shao, MBA, Head of Investment (US) at Simcere Pharmaceutical Group
Jian Shao is responsible for Simcere’s $200 million global life science investment portfolio. He has 14 years of biopharma experience in research, investment and entrepreneurship.
Jonathan Yao, CEO, Linatech, LLC
Jonathan is the chairman of LinaTech Medical Technology & Science Company and a visiting professor at Washington University in St. Louis and a professor at Wuhan University in Wuhan, China.
Joe Xiongwei Zhou, Founder and CEO, Boston Angel Investors
Joe has 20+ years of multi-cultural and multi-national work experience in China, Japan and the U.S.
Come join this timely, lively, keynote presentation and blue-ribbon panel discussion. Ask questions and contribute your insights during the audience interactive segment.
What to Expect
- Funding and investment opportunities for U.S. companies from China Investors
- China BioPharma and Medtech landscape
- Overview of key success factors for China Healthcare market entry
- China’s Healthcare Growth and Market Opportunities
- CFDA Regulatory Changes and Trends
- Should you be concerned about your IP
Who should attend
CEOs, board members, investors, and other senior leaders who want a better understanding of how to maximize their opportunities and gain a better understanding of the China market and investor.